Ulcerative colitis, Crohn's disease and irritable bowel syndrome patients need fecal transplant research and treatment

Article (PDF Available)inJournal of Crohn s and Colitis 8(2) · October 2013with138 Reads
DOI: 10.1016/j.crohns.2013.09.011 · Source: PubMed
Ulcerative colitis, Crohn's disease and irritable
bowel syndrome patients need fecal transplant
research and treatment
Dear Sir,
Dr. Barry Marshall, the Nobel Prize winning Australian
physician, showed that the Helicobacter pylori bacterium was
causing most peptic ulcers, reversing decades of medical
doctrine. A thorough review of the literature suggests that
inflammatory bowel disease (IBD; ulcerative colitis and
Crohn's disease) is related to bacterial dysbiosis (infection via
microorganism, injury, and or imbalance), the cause of
which may be multifactorial. If not, then why are antibiotics
sometimes used to treat IBD? Spouses of Crohn's disease
patients are at an increased risk for the disease.
can cause ulcers in the stomach, s o why would they, and
possibly viruses, not be capable of doing so further down the
gastrointestinal tract? I t is completely plausible. The
immune system has to react t o something.
Another Australian physician, Dr. TJ Borody, suggested
over a decade ago that dysbiosis, or microbial imbalances,
in the intestines may be a major contributing factor to
ulcerative colitis.
He demonstrated that fecal transplants
worked in six cases of ulcerative colitis unresponsive to
other treatments. They used enemas to replenish colons
with bacteria from the gut of a healthy fecal donor. The
researchers wrote, Complete reversal of symptoms was
achieved in all p atients by 4 monthsby which time all
other ulcerative colitis medications had been ceased.
Follow-up articles by Borody indicated that while this
procedure may have to be repeated,
it does not involve
serious drug side-effects or surgical removal of the colon.
Perhaps, herein resides t he answer for ulcerative colitis,
Crohn's disease and even irritable bowel syndrome (IBS)?
The latest news is that fecal transplant has been used
successfully in both of the latter conditions. Despite Borody's
decade old hypothesis, IBD research and funding remained
focused on drugs to reduce symptoms, and not on the real
cause, and therefore real treatment, for IBD. When
researchers started to treat IBD with fecal transplant, the
FDA, quickly declared it a drug in need of an Investiga-
tional New Drug application, prior to further use (4/25/13
Letter). This was after ye ars of allowing it to be used for
Clostridium difficile. Blood or bone samples are not
considered drugs becau se they cannot be replicated, and
neither can fecal material. There are 500,000 to 3,000,000
annual cases of C. difficile, and 14,000 related deaths.
much objection, the FDA reversed its decision and no longer
requires doctors to get approval before using fecal trans-
plant, but only for C . difficile, and not IBD (6/17/13 Letter).
It appears that someone already knows that fecal transfer is a
promising treatment. A breakthrough, other than medical, is
needed to help millions of suffering patients, some of whom
will die.
Conflict of interest statement
I, Amy C. Brown, have no conflict of interest with regard to
this Letter to the Editor.
1. Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk
factors in Crohn's disease and ulcerative colitis: an update.
Gastroenterol Clin Biol 2009;33(Suppl 3).
2. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota trans-
plantation: indications, methods, evidence, and future direc-
tions. Curr Gastroenterol Rep 2013;15(8):337.
3. Borody TJ, Campbell J. Fecal microbiota transplantation: current
status and future directions. Expert Rev Gastroenterol Hepatol
4. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of
ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol
5. McKinney M. FDA slaps regs on fecal transplants. Increased steps
for C. diff treatment draw mixed reactions from providers. Mod
Healthc 2013;43(21):10.
Amy C. Brown
Department of Complementary & Alternative Medicine,
John A. Burns School of Medicine, University of Hawaii at
Manoa,651 Ilalo Street, MEB 223 ,
Honolulu, HI 96813, USA
E-mail address: amybrown@hawaii.edu.
9 September 2013
1873-9946/$ - see front matter © 2013 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.
Available online at www.sciencedirect.com
Journal of Crohn's and Colitis (2013) xx, xxx
CROHNS-00853; No of Pages 1
Please cite this article as: Brown AC, Ulcerative colitis, Crohn's disease and irritable bowel syndrome patients need fecal transplant research
and treatment, JCrohnsColitis(2013), http://dx.doi.org/10.1016/j.crohns.2013.09.011
  • [Show abstract] [Hide abstract] ABSTRACT: Irritable bowel syndrome (IBS) is a common condition characterized by abdominal pain or discomfort, bloating, and altered stool form and passage. Small intestinal bacterial overgrowth (SIBO) is a condition in which there is overgrowth of bacteria in small bowel in excess of 10(5) colony forming units per milliliter on culture of the upper gut aspirate. Frequency of SIBO varied from 4%-78% among patients with IBS and from 1%-40% among controls. Higher frequency in some studies might be due to fallacious criteria [post-lactulose breath-hydrogen rise 20 PPM above basal within 90 min (early-peak)]. Glucose hydrogen breath test (GHBT) has a low sensitivity to diagnose SIBO. Hence, studies based on GHBT might have under-estimated frequency of SIBO. Therefore, it is important to analyze these studies carefully to evaluate whether the reported association between IBS and SIBO is over or under-projected. This review evaluates studies on association between SIBO and IBS, discordance between different studies, their strength and weakness including methodological issues and evidence on therapeutic manipulation of gut flora on symptoms of IBS.
    Article · Mar 2014
  • [Show abstract] [Hide abstract] ABSTRACT: A new frontier of basic human biology has opened up, which is changing our understanding of what constitutes the human body. This new knowledge is fuelling a paradigm shift from the dominant, 20th century view that viruses, bacteria and fungi operated independently to cause disease. Now, we are beginning to view a more complex and nuanced interpretation with increased recognition of the importance of commensalism, synergy and balance of microbiota in human health.1 In this commentary we hope to briefly summarise studies into the bacterial and viral microbiome and how this shifting paradigm affects epidemiology. Metagenomic epidemiology The distribution of human diseases is directly linked to how different people form groups and interact with each other and their environment box 1. This interaction defines a community structure. Community structure has been long recognised as a major determinant of the spread of traditional infectious diseases. Examples range from tuberculosis in crowded slums to the recent spread of Ebola in Africa, where the human behaviours that create community structure often dictate infectious disease spread. These diseases are very sensitive to the social network configuration of the population in which they occur.2 Moreover, social networks within these populations are also important determinants of chronic and traditionally non-infectious diseases. For example, obese individuals are more likely to have other obese individuals as contacts.3 However, even in these ‘non-infectious’ diseases, microorganisms may play a greater role than previously thought. Box 1 Definitions: METAGENOMIC EPIDEMIOLOGY- The study of the distribution and determinants of the microbiome structures and their relationship to disease. MICROBIOTA- A community of microorganisms (viruses, bacteria, fungi, archea) living in a defined niche MICROBIOME- The community of commensal, symbiotic, and pathogenic microorganisms (microbiota) or their genomes sharing the human body. METAGENOME- The totality of non-human nucleic acids belonging to all the microbiotas …
    Full-text · Article · Sep 2014
  • Full-text · Article · Sep 2015